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Abstract Current expectations for successful treatment of
post-traumatic disorders in the CNS are associated with cell-
based technologies. Mesenchymal stem cells, which are under
intensive study, appear to be the most promising. At the same
time, mechanisms of their effect on post-traumatic regeneration
of the spinal cord and their behavior and migration properties in
neurodegenerative lesions are not investigated in full. In our
study, we investigated the survival, migration, and phenotypic
characteristics of a fibrin matrix enclosed in adipose-derived
mesenchymal stem cells (AD-MSCs) by implanting them in
an area of the spinal cord injury in a subacute period. We
showed that adipose-derived mesenchymal stem cells retain
their viability in the area of SCI for up to 60 days and migrate
rostrally and caudally for more than 5mm. Phenotyping of AD-
MSCs in the spinal cord injury area performed on the seventh
day post-transplantation shows that Thy-1, CD 73, and Stro-1
are expressed; however, no CD 44 expression is observed. The
results obtained reveal the route of migration of AD-MSCs
within an area of the spinal cord injury. However, the
programed differentiation of these cells in a later post SCI pe-
riod has to be studied.
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1 Introduction
Spinal cord injury (SCI) is one of current medical and social
problems. In spite of significant advances in surgical and con-
servative therapy and rehabilitation in neuropathology, there
are no effective treatment modalities for spinal cord injuries.
Incapacitation of such patients approaches to 100%, with
high-grade disability prevail [1]. Expectations for successful
treatment of post-traumatic disorders in the CNS are associat-
ed with technologies of regenerative medicine. Its main tool is
cell-based technologies which are widely applied as a thera-
peutic strategy for the treatment of SCI.
Transplanted stem and progenitor cells support the recov-
ery of tissue matrix for nerve fibers regeneration, and have a
trophic effect on neurons and the glia and promote axonal
growth and remyelination. Mesenchymal stem cells (MSCs)
are the most promising for transplantation as they possess
some useful properties, which promote axonal regeneration,
such as: (1) the ability to secret different neurotrophic factors
and cytokines, (2) the ability to differentiate into various cell
types, and (3) immunomodulatory, anti-apoptotic, and anti-
inflammatory effects [2, 3].
Bone marrow is the most common source of bone marrow
mesenchymal stem cells (BM-MSCs). However, technical and
medical difficulties, as well as their decreased number and devel-
opmental potential with age, limit their extensive and successful
use in clinic. Adipose-derived mesenchymal stem cells (AD-
MSCs) are a good alternative to BM-MSCs; they are inferior to
the latter and their obtaining is not associated with to the above
problems. AD-MSCs are intensively investigated in SCI [4–6].
At the same time, mechanisms of their effect on post-traumatic
regeneration of the spinal cord, as well as peculiarities of their
behavior and migration within neurodegeneration lesions are not
clearly understood. Some researchers consider that within the
CNS, MSCs can differentiate into neural progenitor cells, neural
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